NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Trishula Therapeutics

Trishula Therapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://trishulatx.com

Last Round

Spinoff

Aug 26, 2020

Company Overview

Trishula Therapeutics is a biotechnology company that develops cancer immunotherapies, specifically focusing on its first-in-class anti-CD39 antibody, TTX-030.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologycancer immunotherapymonoclonal antibodysolid tumorsclinical trialsdrug developmentoncologybiotechanti-CD39tumor microenvironmentdrug discoveryclinical-stage biotechbiopharmatherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Trishula Therapeutics Comparables

Compare Trishula Therapeutics with similar companies based on industry and business-model similarity.

Trishula Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tizona Therapeutics
91%
Arcus Biosciences
83%
Coherus BioSciences Inc
81%

Trishula Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SpinoffAug 26, 2020

Trishula Therapeutics Investors

Notable investors and investment history

Trishula Therapeutics investors
InvestorRounds
InterWest PartnersSpinoff
Lightstone VenturesSpinoff
MPM BioImpactSpinoff
AbbVie VenturesSpinoff
AbingworthSpinoff
Canaan PartnersSpinoff

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 26, 2020

    Raised a spinoff round with investors including Canaan Partners and AbbVie Ventures.

Trishula Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Trishula Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Trishula Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range10
Year Founded2020
Last FundingAug 26, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.